CREBBP — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL37900	0.47	6/20
SCHEMBL112038	0.43	6/20
SCHEMBL78329	0.62	5/20
SCHEMBL33268	0.55	5/20
SCHEMBL77020	0.50	5/20
SCHEMBL77021	0.50	5/20
SCHEMBL76034	0.47	5/20
SCHEMBL103687	0.40	5/20
SCHEMBL12487	0.62	4/20
SCHEMBL130830	0.51	4/20
SCHEMBL77869	0.51	4/20
SCHEMBL77870	0.51	4/20
SCHEMBL196045	0.45	4/20
SCHEMBL188552	0.43	4/20
SCHEMBL102258	0.40	4/20
SCHEMBL223446	0.54	3/20
SCHEMBL177424	0.53	3/20
SCHEMBL130906	0.49	3/20
SCHEMBL98814	0.43	3/20
SCHEMBL68075	0.41	3/20

Clinical trials — most relevant to CREBBP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.	PHASE3	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Rapid Antidepressant Effects of Yohimbine in Major Depression	PHASE2	COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial)	PHASE2	RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Rosiglitazone to Reverse Metabolic Defects in Diabetes	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Pecos B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat	PHASE2	COMPLETED
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Immune Interactions in Severe Asthma	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
The Effects of HER2 Receptor Signaling on Human Brown Fat Activity	nan	RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
The PRE-OP ENERGY Trial	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CREBBP binder may also engage these)

Protein	Name	Similarity
Q6JHU9	—	1.000	Q6JHU9 →
EP300	Histone acetyltransferase p300	1.000	landscape →
P45481	—	1.000	P45481 →
B2RWS6	—	1.000	B2RWS6 →
Q14686	—	0.995	Q14686 →
Q9JL19	—	0.993	Q9JL19 →
F4I171	—	0.991	F4I171 →
Q15714	—	0.990	Q15714 →
P62501	—	0.989	P62501 →
Q91012	—	0.988	Q91012 →
Q5R4H1	—	0.988	Q5R4H1 →
B2C6R6	—	0.988	B2C6R6 →
Q6DDH6	—	0.987	Q6DDH6 →
BCL9	B-cell CLL/lymphoma 9 protein	0.987	landscape →
Q4V3C1	—	0.987	Q4V3C1 →
Q9JLI4	—	0.987	Q9JLI4 →
Q172Y1	—	0.987	Q172Y1 →
Q63627	—	0.987	Q63627 →
P34545	—	0.987	P34545 →
Q9C5X9	—	0.986	Q9C5X9 →
Q9P267	—	0.986	Q9P267 →
O75157	—	0.985	O75157 →
Q4R4H5	—	0.985	Q4R4H5 →
Q9Y808	—	0.985	Q9Y808 →
Q5F3U0	—	0.985	Q5F3U0 →
A5D7F6	—	0.985	A5D7F6 →
P62500	—	0.984	P62500 →
E9Q7M2	—	0.984	E9Q7M2 →
Q8CHI8	—	0.984	Q8CHI8 →
Q9FWQ5	—	0.984	Q9FWQ5 →